Assessing cognitive effects of anticholinergic medications in patients with coronary artery disease

Psychosomatics

Volumn 55, Issue 1, 2014, Pages 61-68

  Lanctôt, Krista L ^a,b,c   O'Regan, Jordana ^a,b   Schwartz, Yael ^a   Swardfager, Walter ^a,b   Saleem, Mahwesh ^a,b   Oh, Paul I ^a,c   Herrmann, Nathan ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; MUSCARINIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC ACTIVITY; ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; ATTENTION DISTURBANCE; BLOOD BRAIN BARRIER; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; COGNITION; COGNITIVE DEFECT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY RISK; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG EXPOSURE; EXECUTIVE FUNCTION; FEMALE; HOSPITAL PATIENT; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL PERFORMANCE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PROCEDURES; PSYCHOLOGIC TEST; STROOP TEST; STRUCTURED INTERVIEW; VELOCITY; DRUG EFFECTS; NEUROPSYCHOLOGICAL TEST; QUALITY OF LIFE;

ADRENERGIC BETA-ANTAGONISTS; AGED; CHOLINERGIC ANTAGONISTS; COGNITION; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE;

EID: 84891371571     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2013.04.004     Document Type: Article

References (36)

1. Fang J., Shaw K.M., Keenan N.L. Prevalence of coronary heart disease-United States, 2006-2010. MMRW Morb Mortal Wkly Rep 2011, 60:1377-1381.
2. Vinkers D.J., Stek ML, van der Mast RC, et al. Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age. Neurology 2005, 65:107-112.
3. Selnes O.A., Grega MA, Bailey MM, et al. Do management strategies for coronary artery disease influence 6-year cognitive outcomes?. Ann Thorac Surg 2009, 88:445-454.
4. Beeri M.S., Rapp M, Silverman JM, et al. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology 2006, 66:1399-1404.
5. Kiessling A., Henriksson P. Perceived cognitive function is a major determinant of health related quality of life in a non-selected population of patients with coronary artery disease-a principal components analysis. Qual Life Res 2004, 13:1621-1631.
6. Kiessling A., Henriksson P. Perceived cognitive function in coronary artery disease-an unrecognised predictor of unemployment. Qual Life Res 2005, 14:1481-1488.
7. Elias M.F., Dore G.A., Davey A., Robbins M.A., Elias P.K. From blood pressure to physical disability: the role of cognition. Hypertension 2010, 55:1360-1365.
8. Boustani M.A., Campbell N.L., Munger S., Maidment I., Fox G.C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008, 4:311-320.
9. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977, 1:385-401.
10. Hachinski V., Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006, 37:2220-2241.
11. Swardfager W., Herrmann N, Dowlati Y, Oh P, Kiss A, Lanctôt KL Relationship between cardiopulmonary fitness and depressive symptoms in cardiac rehabilitation patients with coronary artery disease. J Rehabil Med 2008, 40:213-218.
12. Swardfager W., Herrmann N, Dowlati Y, Oh P, Kiss A, Lanctôt KL Major depressive disorder predicts completion, adherence, and outcomes in cardiac rehabilitation: a prospective cohort study of 195 patients with coronary artery disease. J Clin Psychiatry 2011, 72:1181-1188.
13. Tune L., Carr S., Hoag E., Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992, 149:1393-1394.
14. Chew M.L., Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008, 56:1333-1341.
15. Campbell N., Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009, 4:225-233.
16. Fox C., Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011, 59:1477-1483.
17. Lechevallier-Michel N., Molimard M., Dartigues J.F., Fabrigoule C., Fourrier-Reglat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol 2005, 59:143-151.
18. Rudolph J.L., Salow M.J., Angelini M.C., McGlinchey R.E. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008, 168:508-513.
19. Pasina L., Djade CD, Lucca U, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging 2013, 30:103-112.
20. Bottiggi K.A., Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006, 14:980-984.
21. Heckman G.A., Patterson CJ, Demers C, St Onge J, Turpie ID, McKelvie RS Heart failure and cognitive impairment: challenges and opportunities. Clin Interv Aging 2007, 2:209-218.
22. Muller M., van der Graaf Y, Visseren FL, Vlek AL, Mali WP, Geerlings MI Blood pressure, cerebral blood flow, and brain volumes. The SMART-MR study. J Hypertens 2010, 28:1498-1505.
23. Okonkwo O.C., Cohen R.A., Gunstad J., Poppas A. Cardiac output, blood pressure variability, and cognitive decline in geriatric cardiac patients. J Cardiopulm Rehabil Prev 2011, 31:290-297.
24. Hajjar I., Quach L, Yang F, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the cardiovascular health study. Circulation 2011, 123:858-865.
25. Schillerstrom J.E., Horton M.S., Royall D.R. The impact of medical illness on executive function. Psychosomatics 2005, 46:508-516.
26. Vazzana R., Bandinelli S, Lauretani F, et al. Trail Making Test predicts physical impairment and mortality in older persons. J Am Geriatr Soc 2010, 58:719-723.
27. Cohen R.A., Moser DJ, Clark MM, et al. Neurocognitive functioning and improvement in quality of life following participation in cardiac rehabilitation. Am J Cardiol 1999, 83:1374-1378.
28. Swardfager W., Herrmann N, Marzolini S, et al. Verbal memory performance and completion of cardiac rehabilitation in patients with coronary artery disease. Psychosom Med 2011, 73:580-587.
29. Kakos L.S., Szabo AJ, Gunstad J, et al. Reduced executive functioning is associated with poorer outcome in cardiac rehabilitation. Prev Cardiol 2010, 13:100-103.
30. Cormack F., Shipolini A, Awad WI, et al. A meta-analysis of cognitive outcome following coronary artery bypass graft surgery. Neurosci Biobehav Rev 2012, 36:2118-2129.
31. Selnes OA O.A., Grega MA, Borowicz LM Jr, Royall RM, McKhann GM, Baumgartner WA Cognitive changes with coronary artery disease: a prospective study of coronary artery bypass graft patients and nonsurgical controls. Ann Thorac Surg 2003, 75:1377-1384. [discussion 1384-6].
32. Neil-Dwyer G., Bartlett J., McAinsh J., Cruickshank J.M. Beta-adrenoceptor blockers and the blood-brain barrier. Br J Clin Pharmacol 1981, 11:549-553.
33. Muldoon M.F., Waldstein SR, Ryan CM, et al. Effects of six anti-hypertensive medications on cognitive performance. J Hypertens 2002, 20:1643-1652.
34. Muldoon M.F., Waldstein S.R., Jennings J.R. Neuropsychological consequences of antihypertensive medication use. Exp Aging Res 1995, 21:353-368.
35. Kersten H., Ruths S., Wyller T.B. Pharmacotherapy in nursing homes. Tidsskr Nor Laegeforen 2009, 129:1732-1735.
36. Mangoni AA, van Munster BC,Woodman RJ, de Rooij SE:Measures of anticholin ergic Q13 drug exposure,serumanticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiatry 2013; Feb 6. doi: pii: s1064-7481(13) 00017-1.10.1016/j.jagp 2013.01.012. e-pub ahead of print.